查看“ROS1 激酶结构域突变”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>ROS1 激酶结构域突变</strong>（ROS1 Kinase Domain Mutations）是指在 <strong>[[ROS1]]</strong> 融合阳性 <strong>[[非小细胞肺癌]]</strong>（NSCLC）患者接受靶向治疗（尤其是第一代药物 <strong>[[克唑替尼]]</strong>）后，肿瘤细胞为逃避药物抑制而发生的获得性<strong>[[耐药突变]]</strong>。由于 ROS1 与 <strong>[[ALK]]</strong> 的激酶结构域具有高度同源性（约 77%），两者的耐药突变谱也非常相似。最常见的耐药突变是位于<strong>[[溶剂前沿]]</strong>的 <strong>[[G2032R]]</strong>（约占耐药病例的 40%），它会导致第一代和部分第二代药物失效。新一代大环内酰胺类抑制剂（如 <strong>[[瑞波替尼]]</strong>、<strong>[[他雷替尼]]</strong>）的设计初衷正是为了克服这一顽固突变。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">ROS1 Mutations</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Acquired Resistance (点击展开)</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                    [Image:ROS1_G2032R_mutation_structure.png]
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">G2032R：ROS1 的“G1202R”</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">涉及基因</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[ROS1]]</strong> (6q22)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">发生背景</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">TKI 治疗进展后</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">最常见突变</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[G2032R]]</strong> (溶剂前沿)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">守门员突变</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[L2026M]]</strong></td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">一代药物</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[克唑替尼]]</strong>, <strong>[[恩沙替尼]]</strong></td>
                </tr>
                 <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">新一代药物</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[瑞波替尼]]</strong>, [[洛拉替尼]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">其他机制</th>
                    <td style="padding: 6px 12px; color: #0f172a;">旁路激活 (KRAS, EGFR)</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">突变全景：从 G2032R 说起</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        ROS1 的突变位点与 ALK 高度对应。由于克唑替尼最初是为 MET 设计的，后来发现对 ALK 和 ROS1 有效，因此这三个激酶的耐药位点（如溶剂前沿区）也表现出惊人的一致性。
    </p>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: center;">
            <tr style="background-color: #eff6ff; color: #1e40af;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 15%;">突变位点</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 20%;">功能分类</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 25%;">克唑替尼<br>恩曲替尼</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 20%;">洛拉替尼<br>(3代)</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 20%;">瑞波替尼<br>他雷替尼</th>
            </tr>
            <tr style="background-color: #f8fafc; font-weight: bold; text-align: left;">
                <td colspan="5" style="padding: 8px 12px; border: 1px solid #cbd5e1; color: #64748b;">I. 溶剂前沿突变 (最常见)</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #b91c1c;"><strong>[[G2032R]]</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">对应 ALK G1202R</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;">高度耐药</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fef9c3; color: #854d0e;">中等/耐药</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;"><strong>敏感</strong></td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">D2033N</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">溶剂前沿</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;">耐药</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td>
            </tr>
            <tr style="background-color: #f8fafc; font-weight: bold; text-align: left;">
                <td colspan="5" style="padding: 8px 12px; border: 1px solid #cbd5e1; color: #64748b;">II. 守门员突变 (Gatekeeper)</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[L2026M]]</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">对应 ALK L1196M</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;">耐药</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td>
            </tr>
            <tr style="background-color: #f8fafc; font-weight: bold; text-align: left;">
                <td colspan="5" style="padding: 8px 12px; border: 1px solid #cbd5e1; color: #64748b;">III. 其他位点</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">S1986Y/F</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">对应 ALK C1156Y</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;">耐药</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">敏感</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心耐药机制：G2032R</h2>
    <div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;">
        <h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">最难攻克的堡垒</h3>
        <p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;">
            <strong>G2032R</strong> 是 ROS1 阳性患者使用克唑替尼后最常见的突变。其机制是位于 <strong>[[ATP结合口袋]]</strong> 溶剂前沿的甘氨酸（Gly, G）突变为精氨酸（Arg, R）。精氨酸巨大的侧链和正电荷产生了强烈的<strong>[[空间位阻]]</strong>和静电排斥，直接把克唑替尼和<strong>[[恩曲替尼]]</strong>“挤”出了结合位点。
        </p>
    </div>
    [Image:Mechanism_of_ROS1_G2032R_resistance.png]

    <h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">新一代药物的突破</h2>
    <p style="margin: 15px 0; text-align: justify;">
        针对 G2032R，新一代 ROS1 抑制剂采用了独特的设计策略：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>[[瑞波替尼]] (Repotrectinib)：</strong>
            <br>一种大环内酰胺类抑制剂。它的分子结构比较紧凑（大环结构），能够精确地折叠进突变后的结合口袋，避开 G2032R 的位阻。临床数据显示，其对 G2032R 突变患者具有显著疗效，已获 FDA 批准。</li>
        <li style="margin-bottom: 12px;"><strong>[[他雷替尼]] (Taletrectinib)：</strong>
            <br>另一种高效的 ROS1/NTRK 抑制剂，对 G2032R 同样表现出优异的抑制活性，且脑透过率高，目前处于后期临床开发阶段。</li>
        <li style="margin-bottom: 12px;"><strong>[[洛拉替尼]] (Lorlatinib)：</strong>
            <br>虽然是 ALK 的三代药，但它对 ROS1 G2032R 的活性较弱（与 ALK G1202R 的高度敏感形成对比）。因此，在 ROS1 领域，洛拉替尼主要用于其他非 G2032R 的耐药突变。</li>
    </ul>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Shaw AT, et al. (2019).</strong> <em>Crizotinib in ROS1-rearranged non-small-cell lung cancer.</em> <strong>[[New England Journal of Medicine]]</strong>.<br>
            <span style="color: #475569;">[奠基之作]：确立了克唑替尼作为 ROS1 阳性肺癌一线治疗的标准地位，但也指出了耐药不可避免的问题。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Gainor JF, et al. (2017).</strong> <em>Molecular mechanisms of resistance to crizotinib in ROS1-positive lung cancer.</em> <strong>[[JCO Precision Oncology]]</strong>.<br>
            <span style="color: #475569;">[机制解析]：通过对耐药患者样本的测序，首次确认 G2032R 是 ROS1 最主要的耐药突变，并指出了其对 Lorlatinib 的不敏感性。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [3] <strong>Drilon A, et al. (2024).</strong> <em>Repotrectinib in ROS1-Fusion-Positive Non-Small-Cell Lung Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>.<br>
            <span style="color: #475569;">[TRIDENT-1研究]：证实了瑞波替尼在 TKI 经治（含 G2032R 突变）患者中具有同类最佳（Best-in-class）的疗效，推动了新药上市。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            ROS1 突变 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联基因</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[ALK]]</strong> (同源性高) • <strong>[[NTRK]]</strong> (结构相似)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心突变</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[G2032R]]</strong> (溶剂前沿) • [[L2026M]] (守门员)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">一代药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[克唑替尼]] • [[恩曲替尼]] (入脑好)</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">下一代药物</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[瑞波替尼]]</strong> • [[他雷替尼]] (AB-106)</td>
            </tr>
        </table>
    </div>

</div>